CoChat

Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Aims/hypothesis: Our aim was to assess treatment discontinuation, reinitiation and switching between drugs within the same drug class for glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes. Methods: We used data from nationwide registers in Sweden to perform separate analyses for all patients with type 2 diabetes who filled a first prescription of a GLP-1 receptor agonist or an SGLT2 inhibitor between 2017 and 2021. Patients were considered to be on treatment for the period during which prescriptions were refilled before the estimated end date of the most recent prescription, including a 90-day grace period, i.e. the time allowed between and after prescriptions before treatment is considered as discontinued. We used the Aalen–Johansen estimator to estimate cumulative incidences of discontinuation and reinitiation, and Fine–Gray sub-distribution hazard models to assess the association of clinical variables with the risk of discontinuation. Results: Among 73,895 new users of GLP-1 receptor agonists, the cumulative incidence of treatment discontinuation was 23.6% at 1 year and 38.5% at 3 years. Among patients who discontinued, the cumulative incidence of treatment reinitiation was 41.1% at 1 year and 57.4% at 3 years after discontinuation. Among 113,207 new users of SGLT2 inhibitors, the cumulative incidence of treatment discontinuation was 27.9% at 1 year and 45.9% at 3 years, with a cumulative incidence of reinitiation of 40.4% at 1 year and 55.7% at 3 years after discontinuation. When varying the grace period between 60 days and 365 days, treatment discontinuation rates at 3 years ranged from 23.3% to 43.6% among GLP-1 receptor agonist users and from 28.8% to 50.6% among SGLT2 inhibitor users. The proportion of patients who had ongoing treatment, regardless of previous discontinuation episodes, ranged between approximately 70% and 80% for both drugs during a 1–5 year period after treatment initiation across analyses using various grace periods. In terms of switching, 22.9% of the GLP-1 receptor agonist users and 2.1% of the SGLT2 inhibitor users switched between drugs within the same drug class. Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors, although the association between higher BMI and a lower likelihood of treatment discontinuation was stronger for GLP-1 receptor agonists. Conclusions/interpretation: Approximately half of type 2 diabetes patients who had started using GLP-1 receptor agonists or SGLT2 inhibitors had discontinued treatment within 5 years of follow-up. However, more than half of those who discontinued treatment subsequently reinitiated treatment, such that the proportion with ongoing treatment was approximately 70–80% for both drugs during a 1–5 year period after treatment initiation. This suggests that the proportion of patients with long-term use of the medications is larger than indicated by analyses focusing on treatment discontinuation. Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-025-06439-x

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Treatment discontinuation (a), treatment reinitiation (b) and the proportion of patients covered by treatment (c) across various lengths of grace period used to define treatment discontinuation among GLP-1 receptor agonist users
Fig. 1 Treatment discontinuation (a), treatment reinitiation (b) and the proportion of patients covered by treatment (c) across various lengths of grace period used to define treatment discontinuation among GLP-1 receptor agonist usersCC BY · PubMed Central
Fig. 2 Treatment discontinuation (a), treatment reinitiation (b) and the proportion of patients covered by treatment (c) across various lengths of grace period used to define treatment discontinuation among SGLT2 inhibitor users
Fig. 2 Treatment discontinuation (a), treatment reinitiation (b) and the proportion of patients covered by treatment (c) across various lengths of grace period used to define treatment discontinuation among SGLT2 inhibitor usersCC BY · PubMed Central
Fig. 3 Treatment discontinuation across subgroups of ASCVD (a), chronic kidney disease (b), heart failure (c) and BMI (d) among GLP-1 receptor agonist users. Cut-offs for BMI classes are given in ESM Table 2. sdHR, sub-distributional HR
Fig. 3 Treatment discontinuation across subgroups of ASCVD (a), chronic kidney disease (b), heart failure (c) and BMI (d) among GLP-1 receptor agonist users. Cut-offs for BMI classes are given in ESM Table 2. sdHR, sub-distributional HRCC BY · PubMed Central
Fig. 4 Treatment discontinuation across subgroups of ASCVD (a), chronic kidney disease (b), heart failure (c) and BMI (d) among SGLT2 inhibitor users. Cut-offs for BMI classes are given in ESM Table 2. sdHR, sub-distributional HR
Fig. 4 Treatment discontinuation across subgroups of ASCVD (a), chronic kidney disease (b), heart failure (c) and BMI (d) among SGLT2 inhibitor users. Cut-offs for BMI classes are given in ESM Table 2. sdHR, sub-distributional HRCC BY · PubMed Central
Fig. 5 Treatment trajectories and switching between drugs within the same drug class for GLP-1 receptor agonists. ‘Other GLP-1 receptor agonists’ comprise exenatide, lixisenatide and dulaglutide
Fig. 5 Treatment trajectories and switching between drugs within the same drug class for GLP-1 receptor agonists. ‘Other GLP-1 receptor agonists’ comprise exenatide, lixisenatide and dulaglutideCC BY · PubMed Central
Fig. 6 Treatment trajectories and switching between drugs within the same drug class for SGLT2 inhibitors. ‘Other SGLT2 inhibitors’ comprise canagliflozin and ertugliflozin
Fig. 6 Treatment trajectories and switching between drugs within the same drug class for SGLT2 inhibitors. ‘Other SGLT2 inhibitors’ comprise canagliflozin and ertugliflozinCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 32

Metadata

Authors
Lim, C.-E., Pasternak, B., Eliasson, B., & Ueda, P.
Affiliations
  • Karolinska Institutet (SE)
  • Statens Serum Institut (DK)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Lim, Carl-Emil
Venue
Diabetologia
Published
2025-05-02
Volume
68
Issue
8
Pages
1680-1695
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4410031675
Cited by
27
References
36
Citations by year
2026: 21 · 2025: 6
FWCI
18.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • ALF Region Stockholm
  • Hjärt-Lungfonden
  • Vetenskapsrådet
  • Karolinska Institute
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
type 2 diabetes, treatment discontinuation, GLP-1 receptor agonists, SGLT2 inhibitors, drug switching, grace period, prescription refills, medication adherence, antidiabetic drug utilization, Aalen-Johansen estimator
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Registries, Sweden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. https://app.cochat.ai/papers/10.1007/s00125-025-06439-x
The paper
Lim, C.-E., Pasternak, B., Eliasson, B., & Ueda, P. (2025). Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-025-06439-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.